D. Western Therapeutics Institute, Inc. (4576.T)

JPY 110.0

(5.77%)

Market Cap (In JPY)

4.56 Billion

Revenue (In JPY)

428.36 Million

Net Income (In JPY)

-812.41 Million

Avg. Volume

3.93 Million

Currency
JPY
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
60.0-249.0
PE
-2.99
EPS
-36.74
Beta Value
0.742
ISIN
JP3548740004
CUSIP
-
CIK
-
Shares
41537073.0
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Yuichi Hidaka
Employee Count
-
Website
https://www.dwti.co.jp
Ipo Date
2009-10-23
Details
D. Western Therapeutics Institute, Inc., a biotechnology company, focuses on discovery and development of various drugs. The company offers GLANATEC and GLA-ALPHA, an ophthalmic solution for the treatment of glaucoma/ocular hypertension; DW-1001, an ophthalmic drug; DWR-2206, a regenerative medicine cell-product for bullous keratopathy; and DW-1002, an ophthalmic surgical adjuvant for cataract surgeries, and ILM, ALC, ERM, and PVR membrane staining. It is also developing DW-5LBT, a lidocaine patch for neuropathic pain after shingles; K-321 to treat fuch endothelial corneal dystrophy which is in Phase III clinical trials; and H-1337, a multi-kinase inhibitor that has started Phase IIb clinical trials for the treatment of glaucoma/ocular hypertension. The company was founded in 1999 and is headquartered in Nagoya, Japan.